Skip to main content
    P

    ProPhase Labs Inc (PRPH)

    Official site

    DIAGNOSTICS & RESEARCH

    $0.00
    +0.00 (+6.52%)

    Last updated: Nov 13, 2026 at 4:00 PM ET

    ProPhase Labs Inc (PRPH) Financials: Revenue, Profit and Cash Flow

    Updated Jun 30, 2026. Financial statements from company filings, amounts in US dollars.

    ProPhase Labs reported revenue of $4.34M for the fiscal year ended Dec 31, 2025, down 35.8% from the year before. That year, net income was -$14.74M with a net margin of -339.3%, operating cash flow was -$8.34M and free cash flow was -$8.34M. The quarter ended Jun 30, 2026 had revenue of $1.01M and net income of -$3.05M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $4.21M, a compound annual rate of 0.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$4.34M-35.8%31.9%-415.4%-339.3%
    Dec 2024$6.77M-80.6%-2.2%-570.6%-788.2%
    Dec 2023$34.98M-71.5%44.5%-60.7%-48.0%
    Dec 2022$122.65M+55.2%57.6%19.2%15.1%
    Dec 2021$79.04M+444.6%53.1%12.4%7.9%
    Dec 2020$14.51M+47.0%31.7%-14.3%-14.6%
    Dec 2019$9.88M-24.8%26.5%-32.8%-31.9%
    Dec 2018$13.13M+33.0%36.4%-12.4%-13.3%
    Dec 2017$9.87M+134.6%19.7%-40.4%411.4%
    Dec 2016$4.21MN/A23.7%-90.2%-68.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$4.34M$6.77M$34.98M$122.65M$79.04M$14.51M$9.88M$13.13M$9.87M$4.21M
    Cost of revenue$2.96M$6.92M$19.43M$51.99M$37.05M$9.91M$7.26M$8.35M$7.92M$3.21M
    Gross profit$1.38M-$150.00K$15.56M$70.65M$41.99M$4.61M$2.62M$4.78M$1.95M$997.00K
    Research and development$107.00K$594.00K$1.40M$652.00K$520.00K$633.00K$332.00K$398.00K$431.00K$358.00K
    Operating income-$18.05M-$38.63M-$21.22M$23.59M$9.80M-$2.08M-$3.24M-$1.63M-$3.99M-$3.79M
    Net income-$14.74M-$53.36M-$16.78M$18.46M$6.27M-$2.13M-$3.15M-$1.74M$40.59M-$2.87M
    EBITDA-$8.67M-$30.52M-$14.61M$28.66MN/A-$1.62M-$2.84M-$1.25M-$3.49M-$3.34M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$1.01M$1.17M$784.00K$883.00K$1.25M$1.43M$1.49M$1.42M$1.50M$2.36M-$5.90M$8.37M
    Gross profit$226.00K$295.00K$247.00K-$123.00K$734.00K$526.00K-$150.00K$215.00K-$155.00K-$60.00K-$3.74M$2.33M
    Operating income-$2.65M-$2.43M-$5.73M-$4.76M-$3.89M-$3.66M-$17.29M-$6.48M-$7.23M-$7.63M-$10.96M-$6.48M
    Net income-$3.05M-$5.17M-$7.40M-$6.84M-$4.47M$3.97M-$34.36M-$6.59M-$6.15M-$6.26M-$8.75M-$5.14M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, short-term debt of $5.16M exceeded cash and equivalents by $5.07M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$59.87M$63.20M$91.93M$87.65M$89.30M$31.41M$12.27M$20.74M$33.66M$12.80M
    Current assets$3.15M$30.64M$47.59M$60.83M$61.32M$15.89M$9.95M$18.24M$28.42M$9.63M
    Cash and equivalents$90.00K$678.00K$1.61M$9.11M$8.41M$6.82M$434.00K$1.55M$3.17M$441.00K
    Total liabilities$56.36M$55.85M$42.54M$24.02M$30.67M$20.85M$1.04M$4.23M$1.81M$6.84M
    Short-term debt$5.16M$3.21M$0$301.00K$663.00K$329.00KN/A$3.59M$0$1.49M
    Long-term debtN/A$11.65M$7.33M$2.40M$10.04M$9.99M$0N/A$0$0
    Shareholder equity$3.51M$7.35M$49.38M$63.63M$58.63M$10.56M$11.23M$16.50M$31.85M$5.96M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$57.41M$58.47M$59.87M$65.70M$42.04M$50.11M$63.20M$91.81M$93.68M$90.03M$91.93M$91.71M
    Total liabilities$60.52M$58.90M$56.36M$58.84M$30.61M$34.99M$55.85M$53.68M$49.60M$45.16M$42.54M$35.28M
    Cash and equivalents$20.00K$31.00K$90.00K$405.00K$169.00K$88.00K$678.00K$501.00K$1.78M$1.18M$2.15M$702.00K
    Shareholder equity-$3.11M-$435.00K$3.51M$6.86M$11.44M$15.12M$7.35M$38.13M$44.08M$44.87M$49.38M$56.43M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$8.34M-$17.54M-$11.89M$28.55M-$13.62M-$2.59M-$841.00K-$2.12M-$2.84M-$472.00K
    Capital expenditures$0$906.00K$2.08M$3.92M$4.23M$1.69M$228.00K$140.00K$208.00K$651.00K
    Free cash flow-$8.34M-$18.44M-$13.97M$24.63M-$17.85M-$4.28M-$1.07M-$2.26M-$3.05M-$1.12M
    Dividends paidN/AN/A$193.00K$9.35M$4.55M$0$5.82M$11.70M$0$0
    Share repurchasesN/AN/A$588.00K$2.15M$917.00K$0N/AN/A$16.28M$0
    Investing cash flow$920.00K$2.42M-$1.37M-$2.08M-$19.67M-$1.02M$5.54M$11.86M$21.77M-$651.00K
    Financing cash flow$6.84M$14.19M$5.76M-$26.02M$35.13M$9.99M-$5.82M-$11.36M-$16.20M-$100.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$78.00K-$748.00K-$1.23M-$3.49M-$247.00K-$3.38M-$3.52M-$4.04M-$4.84M-$5.14M-$753.00K-$4.65M
    Capital expendituresN/A$0N/A$0$0$0$40.00K$1.00K$26.00K$867.00K$239.00K$668.00K
    Free cash flowN/A-$748.00KN/A-$3.49M-$247.00K-$3.38M-$3.56M-$4.04M-$4.87M-$6.01M-$992.00K-$5.32M
    Last 12 quarters

    Frequently Asked Questions About PRPH

    What is ProPhase Labs' annual revenue?

    ProPhase Labs reported revenue of $4.34M for the fiscal year ended Dec 31, 2025.

    How fast is ProPhase Labs' revenue growing?

    Revenue was down 35.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -67.2%.

    Is ProPhase Labs profitable?

    No. ProPhase Labs reported net income of -$14.74M for the fiscal year ended Dec 31, 2025, with a net margin of -339.3%.

    How much free cash flow does PRPH generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$8.34M minus capital expenditures of $0 produced free cash flow of -$8.34M.

    How much debt does ProPhase Labs have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $5.16M and cash and equivalents of $90.00K.